Ascentage Pharma Group International Income Statement

Income Statement Dec2022 Dec2023 Dec2024
Revenue 209.71B221.98B0.13B
Cost of Revenue 22.00B30.54B0.03B
Gross Profit 187.71B191.44B0.13B
Research & Development -743.10B-706.97B0.13B
Selling, General & Administrative -170.59B-181.08B-25.64B
Other Operating Expenses 913.70B888.05B25.51B
Operating Expenses 0.00B0.00B0.00B
Operating Income 187.71B191.44B0.13B
Interest & Investment Income -0.00B-0.01B
Other Non Operating Income 34.78B28.45B0.00B
EBIT 187.71B191.44B0.13B
EBT -887.17B-932.86B-0.05B
Tax Provisions 4.25B7.15B0.00B
Profit After Tax -882.92B-925.71B-0.06B
Equity Income -0.28B-0.00B-0.00B
Income from Non-Controlling Interests -0.07B-0.00B
Income from Continuing Operations -891.42B-940.01B-0.06B
Consolidated Net Income -891.42B-940.01B-0.06B
Income towards Parent Company -882.92B-925.64B-0.06B
Net Income towards Common Stockholders -882.92B-925.64B-0.06B
EPS (Basic) -0.00B-0.00B-0.00B
EPS (Weighted Average and Diluted) -0.00B-0.00B-0.00B
Shares Outstanding (Weighted Average) 0.31B0.31B
EBITDA 187.71B191.44B0.13B